# Pertuzumab Biosimilar, Endotoxin 0.05 EU/mg | Catalog C006P.05

Pertuzumab Biosimilar, Endotoxin 0.05 EU/mg. Pertuzumab biosimilar CHO stable cell line is available for licensing to manufacture the pertuzumab biosimilar protein. The research grade pertuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

## Product Specifications

| | |
|---|---|
| **Catalog No.** | C006P.05 |
| **Product Name** | Pertuzumab Biosimilar, Endotoxin 0.05 EU/mg |
| **Supplier Name** | Syd Labs, Inc. |
| **Brand Name** | Syd Labs |
| **Synonyms** | Anti-ErbB-2 Humanized Monoclonal Antibody, Anti-c-neu Humanized Monoclonal Antibody |
| **Summary** | Recombinant humanized IgG1 Monoclonal Antibody. |
| **Isotype** | Human IgG1 kappa. |
| **Source/Host** | Produced in the pertuzumab biosimilar CHO stable cell line. |
| **Specificity** | Specifically binds to the human HER2/ErbB-2/c-neu. |

## Properties & Storage

| | |
|---|---|
| **Applications** | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab. |
| **Formulation** | 0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives. |
| **Endotoxin** | < 0.05 EU per 1 mg of the protein by the LAL method. |
| **Purity** | >95% by SDS-PAGE under reducing conditions and HPLC. |
| **Shipping** | Shipped with ice pack. Store immediately at recommended temperature. |
| **Storage** | 12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles. |

## Background & Description

Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.